Versant Ventures

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector | Business & Finance | heraldchronicle.com | Business Wire | 9/4/2019

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector Sep 4, 2019 Save SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland–(BUSINESS WIRE)–Sep 4, 2019– Since it was conceived, Versant Ventures has provided enabling support for the design and launch of an independent new venture capital and growth equity investment firm dedicated to the medtech sector. Today Vensana Capital debuted with the closing of its …

Therapeutics startup raises $65M in latest round to fight kidney disease | The Business Journals | 8/24/2019

… operating officer at Seattle Genetics when the company was growing from a development stage to bringing its first product online. Briefly before taking on the role at Chinook, Dobmeier was CEO of another Seattle biotech company, Silverback Therapeutics. After that company hit a preclinical setback, Dobmeier moved on to Chinook, he said. – Staff Writer, Puget Sound Business Journal Aug 23, 2019, 2:18pm PDT Thursday, October 10, 2019 Explore the challenges …

Follow Versant Ventures:    

Chinook Therapeutics bags $65M to bring precision medicine to the kidney | FierceBiotech | 8/22/2019

… need a transplant soon,” Dobmeier told FierceBiotech. Chinook is looking to change that—and it’s raised $65 million from Versant Ventures, Apple Tree Partners and Samsara BioCapital to do so. The Vancouver, Canada-based biotech wants to do for kidney disease what precision medicine has done for cancer treatment. It will use that capital to push “several” precision medicines for rare kidney diseases into the clinic by 2021. FREE DAILY …

VC-backed medical tech startup Ebb Therapeutics appoints president/CEO | PE Hub | 8/22/2019

VC-backed medical tech startup Ebb Therapeutics appoints president/CEO August 22, 2019 By Iris Dorbian Pittsburgh-based Ebb Therapeutics , a medical tech startup, has named Eduard Röösli as president and CEO. His appointment is effective immediately. Previously, he was managing director for Image Skincare . Ebb Therapeutics is backed by KKR, Arboretum Ventures, Versant Ventures and Partner Ventures. PRESS RELEASE PITTSBURGH, Aug. 22, 2019 /PRNewswire/ — Ebb Therapeutics, a med-tech …

Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases | PR Newswire | 8/22/2019

VANCOUVER, British Columbia , Aug. 22, Chinook Therapeutics, Inc. today announced a $65 million Series A financing to discover and develop precision medicines for kidney diseases. Founding investor Versant Ventures led the round with participation by fellow founding investor Apple Tree Partners and new investor Samsara BioCapital. The Series A proceeds will fund the advancement of several kidney disease programs into clinical trials by 2021. “Kidney diseases are a severe and …

VC-backed VenatoRx beefs up team with three new hires | PE Hub | 8/21/2019

VC-backed VenatoRx beefs up team with three new hires August 21, 2019 By Iris Dorbian Malvern, Pennsylvania-based VenatoRx , a pharmaceutical company focused on developing novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections, has expanded its team with three new additions. Jennifer Ellis is now senior vice president of quality; Dr. Paul McGovern is vice president of medical sciences; and Lauren …

Kirk Falconer wrote a new post, Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal, on the site PE Hub | 8/8/2019

Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal August 8, 2019 By Kirk Falconer 2019 © BlueRock Therapeutics LLC Bayer AG has agreed to acquire BlueRock Therapeutics , a Toronto- and Cambridge, Massachusetts-based developer of engineered cell therapies. The deal, expected to close in Q3 2019, values BlueRock at about $1.3 billion (US$1 billion). This includes the 40.8 percent stake currently held by Bayer, a German healthcare …

Bayer to pay $240M to buy BlueRock cell therapy joint venture | FierceBiotech | 8/8/2019

Aug 8, 2019 9:22am BlueRock expects to enter the clinic later this year. (Bayer) Bayer is set to pay $240 million (€214 million) upfront to buy the remaining stake in its cell therapy joint venture, BlueRock Therapeutics. The deal will give Bayer control of an induced pluripotent stem cell (iPSC) pipeline led by a late-preclinical Parkinson’s disease candidate. BlueRock began life in 2016 with a $225 million series A …

PE HUB Wire Highlights, 8.8.19 | 8/8/2019

Centerbridge walks away from $1.5B GoHealth deal; Ardian eyes North America-based companies with next buyout fund; Francisco sells ClickSoftware to Salesforce for $1.4B Happy pre-Friday. A GP of a lower middle market firm told me yesterday that private equity M&A has been down this year. He wondered if the industry is starting to feel the impact of the change in carried interest. In 2017, the Trump administration …

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

… and BlueRock board director. “Our best investments often combine assets, talent and capabilities from multiple geographies. BlueRock is no exception, as it blended science, leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead time. The hope is to produce revolutionary therapeutics that can reverse …

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

… and BlueRock board director. “Our best investments often combine assets, talent and capabilities from multiple geographies. BlueRock is no exception, as it blended science, leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead time. The hope is to produce revolutionary therapeutics that can reverse …

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy | PR Newswire | 8/8/2019

PRNewsfoto/Bayer) (PRNewsfoto/Bayer) BERLIN and CAMBRIDGE, Mass. Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell (iPSC) platform. Following a 2016 joint venture with Versant Ventures to establish BlueRock Therapeutics, Bayer will acquire …

Bayer buys BlueRock in $600 mln bet on stem cell therapies - Nasdaq.com | 8/8/2019

… 2016 joint venture with Versant Ventures, Bayer will acquire the remaining 59.2% stake for about $240 million upfront and an additional $360 million depending on certain development achievements, it said on Thursday. While the biotech firm is looking to treat neurology, cardiology and immunology conditions, its most advanced programme will begin testing on Parkinson’s disease patients by the end of this year in a U.S. regulated trial. “We get access …

Bayer buys Cambridge cell therapy startup BlueRock at $1B value | The Business Journals | 8/8/2019

… for Parkinson’s disease, heart failure and other conditions. BlueRock is the latest preclinical company to be purchased by a large pharmaceutical or biotech firm in recent months. Lexington startup IFM Tre was acquired by Novartis in April, while Tilos Therapeutics was purchased by Merck & Co. in June. BlueRock expects to begin testing its first treatment in humans by the end of the year. Bayer currently has a 41 percent stake …

Bayer buys BlueRock in $600 million bet on stem cell therapies | Yahoo News | 8/8/2019

… by the deal, is working on induced pluripotent stem cells (iPSC), made by reprogramming mature body cells to behave like embryonic stem cells that are injected to restore diseased tissue in patients. While the biotech firm is looking to treat neurology, cardiology and immunology conditions, its most advanced program will begin testing on Parkinson’s disease patients by the end of this year in a U.S. regulated trial. “We get access …

Bayer to acquire biotech BlueRock Therapeutics - MarketWatch | 8/8/2019

Bayer AG BAYRY, +6.54% is acquiring BlueRock Therapeutics, a privately-held U.S.-based biotech developing engineered cell therapies in the areas of neurology, cardiology and immunology, the companies announced Thursday. BlueRock was established in 2016 through a joint venture between Bayer and Versant Ventures. Germany-based Bayer currently holds a 40.8% stake and will acquire the rest for around $240 million. Bayer could also pay an additional $360 million if …

Passage Bio Expands Executive Management Team | Markets Insider | Business Insider | 7/25/2019

PHILADELPHIA, Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced the expansion of the Company’s executive management team. Jill Quigley, J.D., has been appointed chief operating officer and general counsel and Alex Fotopolous has been appointed chief technical officer. The new team joins co-founder and interim chief executive officer, Steve Squinto and co-founder and …

Passage Bio Announces New Dedicated Gene Therapy Manufacturing Suite | Globe Newswire | 7/10/2019

Dedicated cGMP suite to be built under strategic partnership agreement with Paragon Gene Therapy to support future clinical and commercial production for Passage Bio’s AAV-delivered gene therapies July 10, 2019 08:00 ET Source: Passage Bio PHILADELPHIA, July 10, Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases, today announced that it has entered into a collaboration agreement …

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | PR Newswire | 7/3/2019

IRVINE, Calif. , July 2, Inari Medical, Inc. announced today that the company has appointed Thomas M. Tu , M.D. as Chief Medical Officer. Dr. Tu is a pioneer in definitive catheter-based treatment of pulmonary embolism (PE). He was the lead author in the publication of the FLARE trial that resulted in FDA clearance of the FlowTriever device for PE. “I am excited to join Inari Medical, which is poised to …

Century Therapeutics launches to develop stem cell-derived, gene-edited cell therapies for cancer | 7/2/2019

… up to launch with plans to develop off-the-shelf cancer cell therapies , and it has gene editing tools, stem cell technology, and $250 million in financing to do it. The venture capital firm Versant Ventures founded Century in 2018 after watching two cancer cell therapies get approved the year before. Those CAR-T therapies, Kymriah and Yescarta, require taking patients’ immune cells from their bodies, genetically engineering them in …

Biotech

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector | Business & Finance | heraldchronicle.com | Business Wire | 9/4/2019

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector Sep 4, 2019 Save SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland–(BUSINESS WIRE)–Sep 4, 2019– Since it was conceived, Versant … to collaborate on any new opportunities that cross over the biotechnology and medtech sectors. Furthermore, the Versant finance organization is providing back office support for the new medtech fund. About Versant Ventures Versant Ventures is

Therapeutics startup raises $65M in latest round to fight kidney disease | The Business Journals | 8/24/2019

… in the U.S. have been diagnosed with the disease. The recent funding, which was announced Thursday, comes from founding investors Versant Ventures and Apple Tree Partners. Samsara BioCapital also invested. The money will go toward … the role at Chinook, Dobmeier was CEO of another Seattle biotech company, Silverback Therapeutics. After that company hit a preclinical setback, Dobmeier moved on to Chinook, he said. – Staff Writer, Puget Sound Business Journal Aug …

Regenerative Medicine

Kirk Falconer wrote a new post, Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal, on the site PE Hub | 8/8/2019

… held by Bayer, a German healthcare and nutrition business. In 2016, Bayer partnered with U.S. life sciences venture capital firm Versant Ventures in founding BlueRock with a US$225 million financing . Bayer said it will … leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock …

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … leadership and operations across Canada and the U.S.” “Prioritization of regenerative medicine as a new frontier for investment allowed us to develop a position in a new field with two to three years of lead

Food and Drug Administration

VC-backed VenatoRx beefs up team with three new hires | PE Hub | 8/21/2019

… president of medical sciences; and Lauren P. Tornetta has been appointed vice president of regulatory affairs. VenatoRx is backed by Versant Ventures, Abingworth and Foresite Capital. PRESS RELEASE MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today … and commercialization of SivextroTM. SivextroTM was approved by the U.S. Food and Drug Administration in June 2014. Ms. Ellis started her career as an analytical chemist at Alliance Pharmaceuticals, then moved to leading analytical and …

Iris Dorbian wrote a new post, Pfizer to buy VC-backed biotech firm Therachon, on the site PE Hub | 5/9/2019

… as legal advisers to Pfizer. Therachon is backed by Novo Holdings, Cowen Healthcare Investments, Pfizer Ventures, Tekla Capital Management LLC, Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative. PRESS RELEASE NEW YORK & BASEL, Switzerland–(BUSINESS … Designation from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Prior to the closing of the transaction with Pfizer, Therachon will spin-off its apraglutide development program into a separate …

Precision Medicine

Chinook Therapeutics bags $65M to bring precision medicine to the kidney | FierceBiotech | 8/22/2019

Versant Ventures, Apple Tree Partners and Samsara BioCapital to do so. The Vancouver, Canada-based biotech wants to do for kidney disease what precision medicine has done for cancer treatment. It will use that capital to push “several” precision medicines for rare kidney diseases into the clinic by 2021. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every …

Department of Health and Human Services

VC-backed VenatoRx beefs up team with three new hires | PE Hub | 8/21/2019

… president of medical sciences; and Lauren P. Tornetta has been appointed vice president of regulatory affairs. VenatoRx is backed by Versant Ventures, Abingworth and Foresite Capital. PRESS RELEASE MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today … Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300019C, The Wellcome Trust under Award No. 360G-Wellcome-101999/Z/13/Z, and the Biomedical …

VenatoRx Pharmaceuticals to Present at ASM Microbe 2019 | Business & Finance | manchestertimes.com | Business Wire | 6/17/2019

… Health (NIH), Wellcome Trust, CARB-X, and the Defense Threat Reduction Agency (DTRA) as well as private equity investments from Versant Ventures, Abingworth, and Foresite Capital. The Company’s most advanced development-stage product is VNRX … Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201300019C, and The Wellcome Trust under Award No. 360G-Wellcome-101999/Z/13/Z. VenatoRx’s second …

CRISPR

Kirk Falconer wrote a new post, Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal, on the site PE Hub | 8/8/2019

… held by Bayer, a German healthcare and nutrition business. In 2016, Bayer partnered with U.S. life sciences venture capital firm Versant Ventures in founding BlueRock with a US$225 million financing . Bayer said it will … Previous Leaps investments into potentially breakthrough technologies include Casebia Therapeutics (CRISPR/Cas technology to cure severe genetic disorders), BlueRock Therapeutics (iPSC technology to cure cardiovascular and CNS diseases), Joyn Bio (Probiotics for plants to enable …

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … recent examples include Century, Therachon, Black Diamond, Jecure, Inception 5, Crispr and Quanticel. Versant conceived and began to build BlueRock in late 2015 with conviction that stem cells had the potential to produce regenerative therapeutics

ACO

VC-backed VenatoRx beefs up team with three new hires | PE Hub | 8/21/2019

… president of medical sciences; and Lauren P. Tornetta has been appointed vice president of regulatory affairs. VenatoRx is backed by Versant Ventures, Abingworth and Foresite Capital. PRESS RELEASE MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today … joining VenatoRx, Ms. Ellis was Head of Quality Assurance at TRACON, and Vice President of Quality Assurance at Trius Therapeutics, Inc. (acquired by Cubist Pharmaceuticals, Inc.) where she led the GxP Quality activities for development …

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | PR Newswire | 7/3/2019

… a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. He is board-certified in cardiology, interventional cardiology, and is fellowship-trained … device incubator. The company is backed by Gilde Healthcare ( www.gildehealthcare.com ), Versant Ventures ( www.versantventures.com ) and U.S. Venture Partners ( www.usvp.com ). For more information, please visit www.inarimedical.com . Contact Tara Dunn , Vice President Clinical Affairs [email protected] SOURCE Inari …

National Institutes of Health

VC-backed medical tech startup Ebb Therapeutics appoints president/CEO | PE Hub | 8/22/2019

… appointment is effective immediately. Previously, he was managing director for Image Skincare . Ebb Therapeutics is backed by KKR, Arboretum Ventures, Versant Ventures and Partner Ventures. PRESS RELEASE PITTSBURGH, Aug. 22, 2019 /PRNewswire/ — Ebb Therapeutics, a … Therapeutics was funded in part by a grant from the National Institutes of Health, as well as private equity and venture capital firms, KKR, Arboretum Ventures, Versant Ventures and Partner Ventures. To learn more, visit …

VC-backed VenatoRx beefs up team with three new hires | PE Hub | 8/21/2019

… president of medical sciences; and Lauren P. Tornetta has been appointed vice president of regulatory affairs. VenatoRx is backed by Versant Ventures, Abingworth and Foresite Capital. PRESS RELEASE MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today … National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH); Wellcome Trust; the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness …

Medical Research

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors | Business Wire | 4/5/2019

… of apoptotic cell death. Don received his doctorate in biochemistry from the University of Western Ontario and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the … Series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com , and follow us on Twitter and on LinkedIn . Contacts Marissa …

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors | Business & Finance | heraldchronicle.com | Business Wire | 4/5/2019

… of apoptotic cell death. Don received his doctorate in biochemistry from the University of Western Ontario and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the … Series A financing from investors including Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com , and follow us on Twitter and on LinkedIn . View source …

Rare Disease Research

Iris Dorbian wrote a new post, Pfizer to buy VC-backed biotech firm Therachon, on the site PE Hub | 5/9/2019

… as legal advisers to Pfizer. Therachon is backed by Novo Holdings, Cowen Healthcare Investments, Pfizer Ventures, Tekla Capital Management LLC, Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative. PRESS RELEASE NEW YORK & BASEL, Switzerland–(BUSINESS … Cheng, Senior Vice President and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit. “Pfizer’s existing research programs for pediatric growth disorders provide a complementary setting for this potential breakthrough therapy.” “Therachon is a great …

Pfizer Acquires Clinical-Stage Biotech Therachon | Business & Finance | manchestertimes.com | Business Wire | 5/8/2019

Rare Disease Research Unit. “Pfizer’s existing research programs for pediatric growth disorders provide a complementary setting for this potential breakthrough therapy.” “Therachon is a great example of the value that can be built from cutting edge European science,” said Therachon Chairman Tom Woiwode, Managing Director at Versant Ventures. “By coupling that research with a strong group of investors and an exceptional management team, Therachon developed a highly innovative therapy for …

Nextech

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

Nextech Invest led the round, and was joined by investors including BVF Partners , Casdin Capital , Mubadala Ventures , Trinitas Capital , Mirae Asset Capital , Altitude Life Science Ventures , Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

Nextech Invest BVF Partners , Casdin Capital , Mubadala Ventures , Trinitas Capital , Mirae Asset Capital , Altitude Life Science Ventures , Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners …

Pfizer

VC-backed VenatoRx beefs up team with three new hires | PE Hub | 8/21/2019

… president of medical sciences; and Lauren P. Tornetta has been appointed vice president of regulatory affairs. VenatoRx is backed by Versant Ventures, Abingworth and Foresite Capital. PRESS RELEASE MALVERN, Pa.–(BUSINESS WIRE)–VenatoRx Pharmaceuticals today … then moved to leading analytical and CMC project teams at Pfizer, Inc. In her career she has led CMC and Quality groups in the development of compounds in a variety of therapeutic areas. Ms. Ellis …

Why dwarfism start-up Therachon picked Pfizer takeout over IPO | 5/11/2019

PDF Editor’s Note: This article was updated on May 08, 2019 at 5:23 AM PDT Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay $340 million up front for the biotech; its shareholders are eligible for $470 million in milestones. Seeded by Versant Ventures

Ardina

Vividion gets $82mm via Series B financing | 5/1/2019

Versant Ventures, Cardinal Partners, and partner Celgene . The company’s platform is based on work performed at Scripps Research Institute , from which Vividion spun off in 2014. The IP enables the screening of small molecules against all proteins and identifies highly selective binders to previously intractable targets. Series B proceeds will help move lead programs into the clinic and expand the company’s early-stage pipeline. The firm is initially focusing on …

Celgene

Bayer powers Versant cell therapy startup to $250M round | FierceBiotech | 7/1/2019

Versant Ventures’ Century Therapeutics has exited stealth with $250 million to take allogeneic cell therapies into the clinic. Bayer’s VC wing led the investment with the support of Versant and Fujifilm Cellular Dynamics (FCDI). Century … Cell Medica, has come on board as CSO. And longtime Celgene and Roche employee Adrienne Farid, Ph.D., has arrived as chief development officer. This team will be led by Lalo Flores, Ph.D., who helped to

Bristol-Myers

Akero Therapeutics Readies $75 Million IPO - Akero Therapeutics, Inc. (Pending:AKRO) | Seeking Alpha | 6/13/2019

… Akero include venBio Partners, Cormorant Asset Management, LifeSci Venture Partners, Janus Henderson INvestors, Rock Springs Capital, Atlas Venture, Boxer Capital, Versant Ventures, Apple Tree Partners, and Redmile Group among others. Source: Crunchbase Market & Competition According … ABBV ) Allergan ( AGN ) AstraZeneca ( AZN ) MedImmune ( AZN ) Bayer ( OTC:BAYN ) Bristol-Myers Squibb ( BMY ) Eli Lilly and Company ( LLY ) GlaxoSmithKline ( GSK ) Genfit ( GNFT ) Source: Sentieo Financial Status AKRO’s recent financial results are familiar for development …

Jnana Therapeutics Launches With $50 Million Series A Financing to Target the Cell’s Metabolic Gates | Business Wire | 12/15/2017

… inflammatory disorders and neurological diseases. Seed funders Polaris Partners and Avalon Ventures were joined in the Series A syndicate by Versant Ventures, AbbVie Ventures, and Pfizer R&D Innovate. Jnana’s founding team includes recognized leaders … Jnana and former VP and Head of Discovery Chemistry at Bristol-Myers Squibb. Dr. Nashat of Polaris Partners will be joined on Jnana’s board of directors by Kevin Kinsella, founder of Avalon Ventures, and Carlo …

Merck

Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases | PR Newswire | 8/22/2019

… Inc. today announced a $65 million Series A financing to discover and develop precision medicines for kidney diseases. Founding investor Versant Ventures led the round with participation by fellow founding investor Apple Tree Partners and … and prior to that worked internationally at Johnson & Johnson and Merck in various roles leading commercial strategy across all stages of product development including the global launches of INCIVO (telaprevir) and STELARA (ustekinumab). In addition …

Bayer buys Cambridge cell therapy startup BlueRock at $1B value | The Business Journals | 8/8/2019

Merck & Co. in June. BlueRock expects to begin testing its first treatment in humans by the end of the year. Bayer currently has a 41 percent stake in BlueRock three years after forming it with Versant Ventures in 2016. “In line with our strategy to ramp up our investments in technologies with breakthrough innovation potential, we have decided to build our cell therapy pipeline based on BlueRock Therapeutics’ industry-leading …

Therachon

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … new generation of important medicines. Other recent examples include Century, Therachon, Black Diamond, Jecure, Inception 5, Crispr and Quanticel. Versant conceived and began to build BlueRock in late 2015 with conviction that stem cells had

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

Versant Ventures today announced the acquisition of portfolio company BlueRock Therapeutics by Bayer AG for up to $1 billion in total value. For the firm, it represents another in a series of significant transactions by Versant-created companies founded on globally sourced cutting-edge science. A common aspiration of each Versant start-up is to pioneer a new generation of important medicines. Other recent examples include Century, Therachon, Black Diamond …

OrbiMed

Passage Bio Announces New Dedicated Gene Therapy Manufacturing Suite | Globe Newswire | 7/10/2019

OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners, and Vivo Capital. About Paragon Gene Therapy Paragon Gene Therapy, a unit of Catalent Biologics, is an industry leader focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, and oncology immunotherapies. Paragon Gene Therapy has two facilities in Baltimore, Maryland dedicated to process development through commercial manufacturing of most scalable AAV platforms across multiple serotypes …

Passage Bio to Present at Jefferies 2019 Healthcare Conference | Globe Newswire | 5/29/2019

OrbiMed, Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital and Lilly Asia Ventures. For further information, please contact: Sarah McCabe …

Seattle Genetics

Therapeutics startup raises $65M in latest round to fight kidney disease | The Business Journals | 8/24/2019

Staff Writer, Puget Sound Business Journal Aug 23, 2019, 2:18pm PDT Eric Dobmeier , a former Seattle Genetics executive, has a new project and it just raised $65 million in a Series A funding round. Dobmeier … recent funding, which was announced Thursday, comes from founding investors Versant Ventures and Apple Tree Partners. Samsara BioCapital also invested. The money will go toward Chinook’s development of a several oral, small molecule drugs, which

Chinook Therapeutics bags $65M to bring precision medicine to the kidney | FierceBiotech | 8/22/2019

Seattle Genetics veteran at the helm of Chinook Therapeutics. “They say, all I can do is reduce blood pressure and hope they don’t progress to end-stage renal disease and need a transplant soon,” Dobmeier told FierceBiotech. Chinook is looking to change that—and it’s raised $65 million from Versant Ventures, Apple Tree Partners and Samsara BioCapital to do so. The Vancouver, Canada-based biotech wants to do for kidney …

AbbVie

Akero Therapeutics Readies $75 Million IPO - Akero Therapeutics, Inc. (Pending:AKRO) | Seeking Alpha | 6/13/2019

… Akero include venBio Partners, Cormorant Asset Management, LifeSci Venture Partners, Janus Henderson INvestors, Rock Springs Capital, Atlas Venture, Boxer Capital, Versant Ventures, Apple Tree Partners, and Redmile Group among others. Source: Crunchbase Market & Competition According … unchecked. Major competitors that provide or are developing treatments include: AbbVie ( ABBV ) Allergan ( AGN ) AstraZeneca ( AZN ) MedImmune ( AZN ) Bayer ( OTC:BAYN ) Bristol-Myers Squibb ( BMY ) Eli Lilly and Company ( LLY ) GlaxoSmithKline ( GSK ) Genfit ( GNFT ) Source …

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors | Business Wire | 4/5/2019

Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com , and follow us on Twitter and on LinkedIn . Contacts Marissa Picerno Ten Bridge Communications 518-817-2176 [email protected]

Casdin Capital

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

Casdin Capital , Mubadala Ventures , Trinitas Capital , Mirae Asset Capital , Altitude Life Science Ventures , Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial terms weren’t disclosed. • HighTower , which is backed by Thomas H. Lee Partners , made …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

Casdin Capital , Mubadala Ventures , Trinitas Capital , Mirae Asset Capital , Altitude Life Science Ventures , Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners , made an investment in …

Alexandria Venture

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial terms weren’t disclosed. • HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial terms weren’t disclosed …

Alexandria Venture Investments

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial terms weren’t disclosed. • HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial terms weren’t disclosed …

ARCH Venture Partners

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial terms weren’t disclosed. • HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial terms weren’t disclosed …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial terms weren’t disclosed. Advertisement OTHER DEALS …

Altitude Life Science Ventures

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

Altitude Life Science Ventures , Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial terms weren’t disclosed. • HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

Altitude Life Science Ventures , Alexandria Venture Investments , ARCH Venture Partners , Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm …

Cardinal Partners

Term Sheet – Wednesday, May 1 | Yahoo News | 5/1/2019

Versant Ventures , Cardinal Partners and Celgene Corp . PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. Financial terms weren’t disclosed. • HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial terms weren’t disclosed. OTHER DEALS • Curaleaf …

Term Sheet – Wednesday, May 1 - Fortune | 5/1/2019

Versant Ventures , Cardinal Partners and Celgene Corp . Advertisement PRIVATE EQUITY DEALS • Gallant Capital Partners made an investment in Quality Built, a San Diego-based provider of third-party quality assurance services in the residential and commercial construction industry. HighTower , which is backed by Thomas H. Lee Partners , made an investment in LourdMurray , a Beverly Hills, Calif.-based wealth management firm. Financial terms weren’t disclosed. Advertisement OTHER DEALS • Curaleaf Holdings, Inc …

New Enterprise Associates

Metavention, Inc., Closes $65 Million in Series C Funding, Appoints New Chief Executive Officer | Business Wire | 1/9/2018

New Enterprise Associates (NEA) and included participation from new investors Sanderling Ventures, RK Mellon and Horowitz Group, plus existing investors Versant Ventures and a corporate investor. Metavention will use the funds to optimize its novel transcatheter based Metabolic Neuromodulation Therapy (MNT) for glucose control in patients with Type 2 diabetes (T2D) and commence preparations for a Phase 2 study in the United States. MNT has the potential to provide physicians …

Apple Tree Partners

Therapeutics startup raises $65M in latest round to fight kidney disease | The Business Journals | 8/24/2019

Versant Ventures and Apple Tree Partners. Samsara BioCapital also invested. The money will go toward Chinook’s development of a several oral, small molecule drugs, which Dobmeier hopes to bring to clinical trials by 2021. The company, which has 25 employees, was incubated through Versant’s inception sciences discovery engine in Vancouver, B.C., and seeded by Versant and Apple Tree Partners. Dobmeier was most recently was chief operating officer at Seattle Genetics …

Chinook Therapeutics bags $65M to bring precision medicine to the kidney | FierceBiotech | 8/22/2019

Versant Ventures, Apple Tree Partners and Samsara BioCapital to do so. The Vancouver, Canada-based biotech wants to do for kidney disease what precision medicine has done for cancer treatment. It will use that capital to push “several” precision medicines for rare kidney diseases into the clinic by 2021. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every …

Polaris Partners

Kirk Falconer wrote a new post, Canadian VC begins 2019 with heft as top Q1 deals raise $667 mln, on the site PE Hub | 4/18/2019

… KPMG Enterprise . Turnstone, a maker of viral immunotherapies for treating cancer, is backed by FACIT , F-Prime Capital Partners , OrbiMed , Versant Ventures and others. 7) Fiix Software (Toronto) Fiix Software , a maintenance and asset management … with a $25 million (US$18.5 million) Series A financing. Polaris Partners and TenEleven Ventures led, with participation from New Brunswick Innovation Foundation . 10) Avidbots (Kitchener, Ontario) Autonomous connected robots maker Avidbots secured a $24 …

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors | Business Wire | 4/5/2019

Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com , and follow us on Twitter and on LinkedIn . Contacts Marissa Picerno Ten Bridge Communications 518-817-2176 [email protected]

Avalon Ventures

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors | Business Wire | 4/5/2019

Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com , and follow us on Twitter and on LinkedIn . Contacts Marissa Picerno Ten Bridge Communications 518-817-2176 [email protected]

Jnana Therapeutics Appoints Donald Nicholson, Ph.D., as Chair of its Board of Directors | Business & Finance | heraldchronicle.com | Business Wire | 4/5/2019

Avalon Ventures, Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate. For more information, please visit www.jnanatx.com , and follow us on Twitter and on LinkedIn . View source version on businesswire.com : https://www.businesswire.com/news/home/20190405005013/en/ CONTACT: Marissa Picerno …

HCA

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | PR Newswire | 7/3/2019

… CRF. He is also the former chairman of the SCAI-PAC. He is currently interested in new device development and healthcare transformation. “Tom brings deep clinical and advocacy experience to Inari Medical,” said Bill Hoffman … device incubator. The company is backed by Gilde Healthcare ( www.gildehealthcare.com ), Versant Ventures ( www.versantventures.com ) and U.S. Venture Partners ( www.usvp.com ). For more information, please visit www.inarimedical.com . Contact Tara Dunn , Vice President Clinical Affairs [email protected] SOURCE Inari …

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | Markets Insider | Business Insider | 7/2/2019

… CRF. He is also the former chairman of the SCAI-PAC. He is currently interested in new device development and healthcare transformation. “Tom brings deep clinical and advocacy experience to Inari Medical,” said Bill Hoffman … device incubator. The company is backed by Gilde Healthcare (www.gildehealthcare.com), Versant Ventures (www.versantventures.com) and U.S. Venture Partners (www.usvp.com). For more information, please visit www.inarimedical.com. Contact Tara Dunn , Vice President Clinical Affairs [email protected] View original …

Harvard Medical School

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | PR Newswire | 7/3/2019

… solutions, and train many more physician users, Tom’s expertise and perspective will be invaluable.” Dr. Tu is a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and … device incubator. The company is backed by Gilde Healthcare ( www.gildehealthcare.com ), Versant Ventures ( www.versantventures.com ) and U.S. Venture Partners ( www.usvp.com ). For more information, please visit www.inarimedical.com . Contact Tara Dunn , Vice President Clinical Affairs [email protected] SOURCE Inari …

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | Markets Insider | Business Insider | 7/2/2019

… solutions, and train many more physician users, Tom’s expertise and perspective will be invaluable.” Dr. Tu is a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and … device incubator. The company is backed by Gilde Healthcare (www.gildehealthcare.com), Versant Ventures (www.versantventures.com) and U.S. Venture Partners (www.usvp.com). For more information, please visit www.inarimedical.com. Contact Tara Dunn , Vice President Clinical Affairs [email protected] View original …

Massachusetts General Hospital

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | PR Newswire | 7/3/2019

… will be invaluable.” Dr. Tu is a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. He is board-certified in cardiology … device incubator. The company is backed by Gilde Healthcare ( www.gildehealthcare.com ), Versant Ventures ( www.versantventures.com ) and U.S. Venture Partners ( www.usvp.com ). For more information, please visit www.inarimedical.com . Contact Tara Dunn , Vice President Clinical Affairs [email protected] SOURCE Inari …

Inari Medical Appoints Thomas M. Tu, M.D. as Chief Medical Officer | Markets Insider | Business Insider | 7/2/2019

… will be invaluable.” Dr. Tu is a graduate of Harvard Medical School. He completed his medical and cardiology training at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. He is board-certified in cardiology … device incubator. The company is backed by Gilde Healthcare (www.gildehealthcare.com), Versant Ventures (www.versantventures.com) and U.S. Venture Partners (www.usvp.com). For more information, please visit www.inarimedical.com. Contact Tara Dunn , Vice President Clinical Affairs [email protected] View original …

Memorial Sloan Kettering

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing expertise from partners. In December 2016, BlueRock came out of

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland- Versant Ventures today announced the acquisition of portfolio company BlueRock Therapeutics by Bayer AG for up to $1 billion in total value. For the firm, it … Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing expertise from partners. In December 2016, BlueRock came out of

Cedars-Sinai Medical Center

Inari Medical Announces Completion of Patient Enrollment in the FLARE Study for the Treatment of | PR Newswire | 10/24/2017

… strong collaboration between a talented group of physician investigators,” added Victor Tapson , MD, Associate Director, Pulmonary and Critical Care Division, Cedars-Sinai Medical Center, Los Angeles and Co-Principal Investigator of the study. “We appreciate … Medical, a medical device incubator. The company is backed by Versant Ventures, U.S. Venture Partners, the founders, and other private investors. For more information, please visit www.inarimedical.com . releases/inari-medical-announces-completion-of-patient-enrollment …

Inari Medical Announces Completion of Patient Enrollment in the FLARE Study for the Treatment of Pulmonary Embolism | PR Newswire | 10/24/2017

… strong collaboration between a talented group of physician investigators,” added Victor Tapson , MD, Associate Director, Pulmonary and Critical Care Division, Cedars-Sinai Medical Center, Los Angeles and Co-Principal Investigator of the study. “We appreciate … Medical, a medical device incubator. The company is backed by Versant Ventures, U.S. Venture Partners, the founders, and other private investors. For more information, please visit www.inarimedical.com …

Health Net

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

Bayer AG buys BlueRock Therapeutics for $1 bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE … technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland- Versant Ventures today announced the acquisition of portfolio company BlueRock Therapeutics by Bayer AG for up to $1 billion in total value. For the firm, it … technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing

Justin Klein

Metavention, Inc., Closes $65 Million in Series C Funding, Appoints New Chief Executive Officer | Business Wire | 1/9/2018

… New Enterprise Associates (NEA) and included participation from new investors Sanderling Ventures, RK Mellon and Horowitz Group, plus existing investors Versant Ventures and a corporate investor. Metavention will use the funds to optimize its novel … one of the underlying causes of Type 2 diabetes.” Added Justin Klein, M.D., J.D., Partner at New Enterprise Associates “NEA is proud to partner with the Metavention team to advance a highly innovative medical device …

Marcela Maus

Bayer powers Versant cell therapy startup to $250M round | FierceBiotech | 7/1/2019

Versant Ventures’ Century Therapeutics has exited stealth with $250 million to take allogeneic cell therapies into the clinic. Bayer’s VC wing led the investment with the support of Versant and Fujifilm Cellular Dynamics (FCDI). Century … to build on the research of the biotech’s scientific cofounders, Marcela Maus, M.D., Ph.D., of Harvard Medical School and Hiro Nakauchi, M.D., Ph.D., of Stanford University School of Medicine. A partnership with Fujifilm subsidiary FCDI

Kirk Falconer

Kirk Falconer wrote a new post, Bayer to acquire VC-backed BlueRock Therapeutics in $1.3 bln deal, on the site PE Hub | 8/8/2019

Kirk Falconer 2019 © BlueRock Therapeutics LLC Bayer AG has agreed to acquire BlueRock Therapeutics , a Toronto- and Cambridge, Massachusetts-based developer of engineered cell therapies. The deal, expected to close in Q3 2019, values BlueRock at about $1.3 billion (US$1 billion). This includes the 40.8 percent stake currently held by Bayer, a German healthcare and nutrition business. In 2016, Bayer partnered with U.S. life sciences venture capital firm Versant …

Kirk Falconer wrote a new post, Canadian VC begins 2019 with heft as top Q1 deals raise $667 mln, on the site PE Hub | 4/18/2019

Canadian VC begins 2019 with heft as top Q1 deals raise $667 mln April 18, 2019 Print Email Photo courtesy of DNY59/iStock/Getty Images After nine straight years of growth, Canada’s venture capital market showed no signs of slowing down in early 2019. The top 10 first-quarter VC financings drew $667 million from VC funds. While that’s down 28 percent from the $923 million raised by the top …

Mikael Dolsten

Iris Dorbian wrote a new post, Pfizer to buy VC-backed biotech firm Therachon, on the site PE Hub | 5/9/2019

… as legal advisers to Pfizer. Therachon is backed by Novo Holdings, Cowen Healthcare Investments, Pfizer Ventures, Tekla Capital Management LLC, Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative. PRESS RELEASE NEW YORK & BASEL, Switzerland–(BUSINESS … it is found inside or outside of our labs,” said Mikael Dolsten, Pfizer Chief Scientific Officer and President, Worldwide Research, Development, and Medical. “By acquiring Therachon, we hope to leverage Pfizer’s leading scientific and development …

Pfizer Acquires Clinical-Stage Biotech Therachon | Business & Finance | manchestertimes.com | Business Wire | 5/8/2019

… the most promising science in the world, regardless of whether it is found inside or outside of our labs,” said Mikael Dolsten, Pfizer Chief Scientific Officer and President, Worldwide Research, Development, and Medical. “By acquiring … European science,” said Therachon Chairman Tom Woiwode, Managing Director at Versant Ventures. “By coupling that research with a strong group of investors and an exceptional management team, Therachon developed a highly innovative therapy for a …

Tony Johnson

Chinook Therapeutics bags $65M to bring precision medicine to the kidney | FierceBiotech | 8/22/2019

… and need a transplant soon,” Dobmeier told FierceBiotech. Chinook is looking to change that—and it’s raised $65 million from Versant Ventures, Apple Tree Partners and Samsara BioCapital to do so. The Vancouver, Canada-based … cancer—all types—with one drug. RELATED: In conversation with Tony Johnson, CEO of Goldfinch Bio What’s more, kidney disease has been treated as a symptom of other disease, as a symptom of high blood …